Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior weight loss and expanded therapeutic applications spanning from brain health to renal disease". Lillys Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade Davy James Key Takeaways Eli Lilly's orforglipron and retatrutide are pivotal in the cardiometabolic market, with significant sales projections by 2031
KLOW80 combines four peptides in one vial for researchers who want to study their combined effects without reconstituting each individually
Letrozole competitively inhibits the active site of the aromatase enzyme
ClinicalTrials.gov ID NCT06564753 Results: Body Weight Reductions The 13-week MAD study showed NA-931 demonstrated dose-dependent reductions in mean body weight from baseline, up to 13.8 % at 150 mg daily dosage, or 12.4% % relative to placebo
Only about 10% are extremely high-weight-loss patients, having lost 80 to 100 pounds or more, he says
doi:10.1001/jamanetworkopen.2022.13242 Dietary Meat, Trimethylamine N-Oxide-Related Metabolites, and Incident Cardiovascular Disease Among Older Adults: The Cardiovascular Health Study, Arteriosclerosis Thrombosis and Vascular Biology (2022)
